Page 123 - Memoria SEHH 2022

MEMORIA ANUAL 2022 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GESMD
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
• The Molecular International Prognostic Scoring System (IPSS-M) for risk stratifica- tion in myelodysplastic syndromes.
New Engl J Med Evidence. 2022;1(7). DOI: 10.1056/EVIDoa2200008.
Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, Devlin SM, Creignou M, Pinel P, Monnier L, Gundem G, Medina-Martínez JS, Werner Y, Jädersten M, Germing U, Sanz G, Van De Loosdrecht AA, Kosmider O, Follo MY, Thol F, Palomo L, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase D, Ganster C, Ades L, Tobiasson M, Della Porta MG, Takaori AK, Ishikawa T, Chiba S, Kasahara S, Miyazaki Y, Viale A, Huberman K, Fenaux P, Belickova M, Savona MR, Klimek VM, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Solé F, Platzbecker U, Heuser M, Valent P, Ohyashiki K, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Gattermann N, Ebert BL, Béjar R, Malcovati L, Cazzola M, Ogawa S, Hellström-Lindberg E, Papaemmanuil E .
• Pathophysiologic and clinical implications of molecular profiles resultant from dele- tion 5q.
EBioMedicine. 2022 Jun;80:104059. doi: 10.1016/j.ebiom.2022.104059.
Adema V, Palomo L, Walter W, Mallo M, Hutter S, La Framboise T, Arenillas L, Meggendor- fer M, Radivoyevitch T, Xicoy B, Pellagatti A, Haferlach C, Boultwood J, Kern W, Visconte V, Sekeres M, Barnard J, Haferlach T, Solé F, Maciejewski JP .
• Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.
Cancers (Basel). 2022 Aug 25;14(17):4107. doi: 10.3390/cancers14174107.
Castaño-Díez S, López-Guerra M, Bosch-Castañeda C, Bataller A, Charry P, Esteban D, Guijarro F, Jiménez-Vicente C, Castillo-Girón C, Cortes A, Martínez-Roca A, Triguero A, Álamo JR, Beà S, Costa D, Colomer D, Rozman M, Esteve J, Díaz-Beyá M .
• Relevance of infections on the outcomes of patients with myelodysplastic syn- dromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD.
Ther Adv Hematol. 2022 Sep 29;13:20406207221127547. doi: 10.1177/20406207221127547. Vilorio-Marqués L, Castañón Fernández C, Mora E, Gutiérrez L, Rey Bua B, Jiménez Lo- renzo MJ, Díaz Beya M, Vara Pampliega M, Molero A, Sánchez-García J, Calabuig M, Ce- dena MT, Chen-Liang T, Díaz Santa JA, Padilla I, Hernández F, Díez R, Asensi P, Xicoy B, Sanz G, Valcárcel D, Díez-Campelo M, Bernal T .
• CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Blood. 2022 Jul 7;140(1):38-44. doi: 10.1182/blood.2021014840.
123